Mounting evidence indicates that TREM2 may modulate AD-related neuropathology by suppressing the inflammatory response, increasing Aβ phagocytosis, ameliorating tau pathology and promoting neuronal survival, thus contributing to neuroimmune homeostasis (Yeh et al., 2017). The gene discussed is MAPT; the disease is Alzheimer disease.